Kornimate/medical-research-clean huggingface dataset:
prolactin receptor and breast diseases

Conditions: Benign Breast Disease; Breast Cancer

Summary: prolactin is known to play an important role in breast development and differentiation. thus proliferative breast diseases are good models to unravel prl / prlr function in proliferative processes. the aim of this project is to identify and to characterize new mutants of the prolactin receptor gene within cohorts of benign or malign breast diseases with low or high occurrence frequency in human populations

there is currently no known genetic disease linked to prolactin (prl) or its receptor (prlr) in humans. in a previous work, we have identified a new mutation of prolactin receptor that leads to it's constitutive activation and to cell proliferation signalling cascades (i.e. through map kinases). this result suggests that prlr mutants may have a strong physiopathological impact on breast diseases etiology and/or development and/or evolution. based on this, we will pursue the identification of new prlr mutants in various breast diseases and continue their in vitro functional characterization and then analyse their in vivo consequences on breast tissue samples collected within these women. 1. in a first time we wish to confirm our previous results on multiple fibroadenomas (mfa). the current cohort will be augmented with 30 to 35 new patients each year. we will confirm our in vitro results in vivo with tumoral and peri-tumoral tissue samples. 2. we then wish to extend this study to other rare breast pathologies (i.e. gigantomastia, phyllodies tumors, giant fibroadenomas) and to more common ones (simple fibroadenomas) to demonstrate a link between simple fa and mfa. 3. in a third time we will try to determinate whether a constitutive activation of prlr leads to enhanced occurrence of benign / malign transitions.

Eligibility criteria:
inclusion criteria : * benign breast diseases * 10 \< age \< 25 for simple fa * 10 \< age \< 50 for other diseases .no hormonal treatment for at least 3 months if patients took cyproterone acetate; 1 month for other ovaries-interfering hormonal treatment, and 1 week for ovaries-non-interfering hormonal treatments. * signature of the informed consent form (icf) by patients or their legal representative (for patients under age of 18.) * breast cancer : * having a breast cancer with a planned surgery * age \> 55 years * post menopausal with not menopause substitution treatment * signature of the icf * control group : * 18 \< age \< 60 * signature of the icf exclusion criteria : * no signature or no conformity of the icf * no social security

Keywords: breast diseases, human mutation, prolactin receptor; breast cancer
low-dose ketamine infusion during burn wound care

Conditions: Burn; Pain; Dissociation; Opioid

Summary: the current standard of care (soc) (i.e. fentanyl and midazolam) offers limited efficacy for preventing or relieving pain. ketamine infusions may provide the benefits of analgesia, minimize adverse events, and reduce opioid use. the purpose of this study is to determine if adding a low dose ketamine infusion during wound care will safely provide pain relief for patients with burn injury.


Eligibility criteria:
inclusion criteria: * admitted to burn service with thermal injury exclusion criteria: * unable/unwilling to consent within 72 hours * unable to report nrs * known contraindication to ketamine * \< than 18 years of age * pregnant * incarcerated * tbsa over 50 %

Keywords: ketamine burn opioid analgesia
curative proton beam therapy for patients with liver metastasis of colorectal cancer

Conditions: Colorectal Cancer

Summary: proton alone therapy is performed -\> 5 times a week, 7200 cgy / 15 fractions for 3 weeks total

this clinical trial is a prospective, single-organ, phase ii clinical trial to evaluate the efficacy of curative proton therapy for liver metastasis of colorectal cancer diagnosed histologically as adenocarcinoma. patients who meet the selection criteria should be selected, signed for consent, and treated 5 times a week for 7200 cgy / 15 fractions alone for 3 weeks.

Eligibility criteria:
inclusion criteria: 1. histologically diagnosed colon adenocarcinoma in primary or metastatic lesions.. 2. if there is no other remote metastasis other than liver, or if there is, control is possible 3. if there are less than 2 liver metastatic lesions 4. if they refuse lung surgery or surgery is inappropriate (medically unsuitable for surgery due to surgery refusal, diabetes mellitus, high blood pressure, pulmonary disease, heart disease, etc., repeated surgery, poor systematic function, short disease-free period, etc.) exclusion criteria: 1. other histologic cancer other than adenocarcinoma of the colorectal 2. colorectal cancer without primary lesion resection 3. if there is another remote metastasis and is not completely resected or regulated 4. if the patient has experience of other invasive cancer diagnosis within 5 years of colorectal cancer diagnosis 5. pregnancy and women under lactation

Keywords: liver metastasis, curative proton beam therapy
efficacy of tranexamic acid in reducing myomectomy associated blood loss in federal teaching hospital abakaliki.

Conditions: To Determine Efficacy of Tranexamic Acid in Reducing Blood Loss During Myomectomy

Summary: to determine safety and efficacy of tranexamic acid in reducing blood loss during myomectomy in our institution.

a double blinded randomized controlled trial in which cases were given 1000mg intravenous tranexamic acid into 1l of intravenous normal saline and control were given 10mls of placebo water for injection into same amount of intravenous fluid. outcome of both groups in terms of intraoperative blood loss, duration of surgery, postoperative packed cell volume and total blood loss with risk of blood transfusion were then determined.

Eligibility criteria:
inclusion criteria: * non-pregnant women with symptomatic myomas women with no known contraindication to tranexamic acid exclusion criteria: * past history of thromboembolic disorder, ischaemic heart disease, malignancy or liver disease

Keywords: tranexamic acid, myomectomy, blood loss, gravimetric
village-based intervention for late-life depression

Conditions: Depression

Summary: investigators aimed to examine the feasibility and effectiveness of a village-based multilevel intervention for late-life depression. two small rural villages in rural south korea were selected as the intervention group and active control. all older adults living in the two villages were included in the intervention program or received standard cmhs care, and the effectiveness of the program was examined using representative samples from both groups.

objectives: to examine the feasibility and effectiveness of a village-based multilevel intervention for late-life depression, focusing on strengthening the autonomy of village-dwellers with help from the community mental health service (cmhs). design: a community-based randomized trial with participants (all village-dwellers) assigned to two parallel programs: intervention program or the cmhs's usual care. setting: two small villages in a rural area of south korea participants: all older adults (aged ≥65 years) living in the two villages were included in the intervention or the cmhs's usual care, and the effectiveness of the program was examined using representative samples who were age- and sex-stratified randomly selected from both groups. intervention: a 12-week intervention was comprised of individual-based risk-stratified case management and group-based activities. measurements: the korean version of geriatric depression scale-short form (sgds-k) was used as the primary outcome while depressive episodes, suicidal ideation/plans/attempts, social network, functional status, and global cognitive function were measured as secondary outcomes.

Eligibility criteria:
inclusion criteria: * all community-dwelling older adults, aged 65 years and over exclusion criteria: * subjects who had significant sensory deficits or medical illnesses that would substantially restrict the delivery of the assessment were excluded

Keywords: old-aged community-based intervention late-life depression suicide
the short form-36: pre- versus post-surgical administration in cardiac surgery patients

Conditions: Coronary Artery Bypass Grafting; Heart Diseases; Heart Valve Diseases

Summary: the purpose of this study is to determine whether the sf-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.

the purpose of this study, is to determine whether the sf-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.

Eligibility criteria:
inclusion criteria: * cardiac surgery patients who are between the ages of 18 and 100 * are english speaking * able to give consent * undergoing cardiac surgery including (but not limited to): * aortic valve replacement (avr) * mitral valve replacement (mvr) * tricuspid valve replacement (tvr) * coronary artery bypass graft (cabg). exclusion criteria: * non-cardiac surgery patients

Keywords: cardiac surgery patients quality of life recall bias aortic valve replacement mitral valve replacement tricuspid valve replacement coronary artery bypass graft surgery
letrozole plus low-dose metronomic capecitabine versus ec-t (epirubicin/cyclophosphamide followed by docetaxel) as neoadjuvant therapy for er+/her2-negative breast cancer

Conditions: Breast Cancer

Summary: patients with er+/her2- breast cancer (presumably the luminal a subtype) could potentially avoid the standard chemotherapy use. letrozole plus low-dose metronomic capecitabine may offer similar efficacy and less toxicity to standard chemotherapy in er+/her2- breast cancer patients.


Eligibility criteria:
inclusion criteria: -women (age 18-70 years) with clinical t2-3 n0-1 m0 er-positive (er) allred score 4-8，and progesterone receptor-positive (pgr) ，her2-negative adequate bone marrow reserve (wbc count, 3.5 \*109/l; platelets, 100\*109/l; hemoglobin, 10g/dl), hepatic function (ast/alt bilirubin and alkaline phosphatase levels 1.25 the upper limit of normal value), and renal function (serum creatinine 1.25 the upper limit of normal value). luminal a/ lymph node positive breast cancer or luminal b breast cancer patients exclusion criteria: * (a) male patients; (b) patients with inflammatory breast cancer or distant metastasis; (c) patients who were previously treated with chemotherapy, radiation therapy or prior treatment with ais or antiestrogens for breast cancer; (d) patients with a second concomitant neoplasm; and (e) patients who could not meet the eligibility criteria.

Keywords: letrozole metronomic capecitabine neoadjuvant chemotherapy er+/her2-
copd-icu multicentre prospective observational register

Conditions: COPD Exacerbation Acute

Summary: copd is one of the leading causes of morbidity, mortality and health care utilisation worldwide. currently, copd is the third leading cause of death worldwide and is therefore a major public health problem. projections show an increase in the prevalence and burden of copd in the coming decades due to ageing populations and continued exposure to risk factors. in patients with copd, mortality due to exacerbations is about 35%. exacerbations represent the most important respiratory event in the history of this chronic disease and are of major socio-economic interest (about 50-75% of healthcare expenditure in this disease). in the most severe cases, copd exacerbations lead to respiratory distress with hypercapnic ventilatory acidosis requiring ventilatory support. these most severe episodes are common, accounting for 20% of exacerbations and are a signal of advanced disease, with a high risk of future hospitalisations and a limited long-term prognosis. despite progress in management, the mortality of these severe acute exacerbations is around 15% in the icu and 20% in hospital. the long-term prognosis following hospitalisation for an acute exacerbation of copd is poor with a 5-year mortality of around 50%. on the one hand, the means and treatments likely to improve the prognosis of these patients are of great medical and socio-economic interest, on the other hand, it seems important to identify the elements that may be associated with management failure and to treat them where appropriate. thus, improving scientific knowledge thanks to prospective data, evaluating the different characteristics and prognosis of patients hospitalised for a severe acute exacerbation of copd seems, in the 21st century, a major axis in order to continue to optimise the individual management of these patients but also collectively, given the copd public health burden.


Eligibility criteria:
inclusion criteria: 1. age ≥ 40 years old 2. copd documented or strongly suspected * chronic respiratory symptoms (dyspnoea, cough and/or sputum) * exposure to a known risk factor for copd (such as tobacco smoke) * if available, respiratory function tests showing non- or partially reversible obstructive syndrome (post-bronchodilator ratio fev1/cv \< 0.7) 3. severe acute exacerbation, defined as a worsening of the patient's usual respiratory symptoms with signs of acute respiratory distress (polypnoea ≥ 30 cycles.min-1 or use of accessory respiratory muscles) and/or hypercapnic acidosis (with paco2 ≥ 45 mmhg and ph ≤ 7.35) 4. admission to an icu, or a dedicated respiratory intensive care unit exclusion criteria: 1. known asthma (according to the criteria of the international "global initiative for asthma" guidelines) 2. patient refusal to participate (information note, application for non-opposition)
a study to evaluate iloperidone for the treatment of parkinson's disease psychosis

Conditions: Parkinson Disease Psychosis

Summary: this is an open-label, sequential cohorts, flexible dose study to evaluate the tolerability, safety and pharmacokinetics of iloperidone in elderly patients with parkinson's disease psychosis (pdp).


Eligibility criteria:
inclusion criteria: * willing and able to provide consent and willing to complete all aspects of the study. * male or female patients greater or equal to 65 years of age. * clinical diagnosis of idiopathic parkinson's disease with a minimum duration of 1 year * psychotic symptoms for at least one month and actively experiencing psychotic symptoms each week during the month prior to screening exclusion criteria: * history of significant psychotic disorders prior to or concomitantly with the diagnosis of parkinson's disease including, but not limited to, schizophrenia or bipolar disorder * current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the study
the effects of mechanical insufflation-exsufflation on airway mucus clearance in the icu

Conditions: Respiratory Failure

Summary: the present study aims to evaluate the effect of mechanical insufflation-exsufflation on airway mucus clearance among mechanically ventilated icu patients. a parallel group randomized clinical trial will be conducted in a single mixed medical-surgical icu of a tertiary hospital in southern brazil. adult icu patients with a length of mechanical ventilation \>24 hours will be evaluated for eligibility. patients will be randomized in a 1:1 ratio to receive respiratory physiotherapy using a mechanical insufflation-exsufflation device (intervention group) or standard respiratory physiotherapy without the use of the mechanical insufflation-exsufflation device (control group). the primary outcome is the amount of aspirated respiratory mucus (weight in grams) 5 minutes after the finish of respiratory physiotherapy.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * admission to the icu * length of mechanical ventilation \> 24 hours * stable ventilatory and hemodynamic status defined by positive end- expiratory pressure ≤ 8 cm h2o, inspiratory oxygen fraction ≤ 40%, ratio of arterial oxygen partial pressure to fractional inspired oxygen ≥ 150, respiratory rate ≤ 35 breaths per minute, heart rate ≤ 130 beats per minute and systolic blood pressure between 90 and 160 mmhg. exclusion criteria: * patients with primary neuromuscular disease. * patients in exclusive paliative care. * patients with contraindications to the use of mechanical insufflation- exsufflation device.

Keywords: respiratory failure mechanical ventilation mechanical insufflation-exsufflation airway mucus clearance
grn1005 in non-small cell lung cancer (nsclc) patients with brain metastases (grabm-l)

Conditions: Non-small Cell Lung Cancer (NSCLC) With Brain Metastases

Summary: the purpose of this study is to assess the efficacy, safety, and tolerability of grn1005 in patients with brain metastases from non-small cell lung cancer (nsclc).


Eligibility criteria:
key inclusion criteria: 1. adult patients (≥ 18 years) 2. histologically or cytologically-documented nsclc (egfr mutation status must be known) 3. brain metastases from nsclc, which: have radiologically-progressed after wbrt or are present without prior wbrt 4. at least one radiologically-confirmed and measurable lesion (≥ 1.0 cm in the longest diameter) within14 days prior to the first dose of grn1005 (cycle 1, day 1), as follows: an intra-cranial disease lesion (≥ 1.0 cm in the longest diameter) confirmed by gd-mri, or an extra-cranial disease lesion (≥ 1.0 cm in the longest diameter) confirmed by mri or ct scan with contrast prior stereotactic radiosurgery (srs) is allowed; however, metastatic brain lesions previously treated with srs are not allowed as target or as non-target lesions. 5. patients must be neurologically stable, defined as being on stable doses of corticosteroids and anticonvulsants (not eiaeds, including phenytoin, phenobarbitol, carbamazepine, fosphenytoin, primidone, oxcarbazepine) for ≥ 5 days prior to obtaining the baseline gd-mri of the brain and ≥ 5 days prior to first dose of grn1005 (cycle 1, day 1). 6. karnofsky performance score (kps) ≥ 80% 7. completed wbrt for intra-cranial lesions ≥ 28 days prior to first dose of grn1005 (with the exception of local radiation therapy for palliation to extra-cranial sites, i.e., bone). all clinically significant toxicities must have resolved to ≤ nci ctcae v4.0 grade 1.0. key exclusion criteria: 1. nci ctcae v4.0 grade ≥ 2 neuropathy 2. cns disease requiring immediate neurosurgical intervention (e.g., resection, shunt placement, etc.) 3. known intra-cranial hemorrhage 4. known leptomeningeal disease

Keywords: grn1005 ang1005 lrp-1 targeted therapy brain tumor blood brain barrier peptide-drug conjugate (pdc) brain metastases paclitaxel taxol nsclc non-small cell lung cancer
scd163 and smr in wilsons disease - associations with disease severity and fibrosis

Conditions: Wilsons Disease

Summary: the aim is to investigate macrophage activation markers and correlations to liver fibrosis in patients with wilsons disease. researchers wish to investigate associations to neurologic and metabolic liver function. researchers will assess this by comparing blood samples with fibrosis and liver function analyses. this study provides new insight into macrophages and their involvement in wilsons disease.


Eligibility criteria:
inclusion criteria: * diagnosed with wilsons disease exclusion criteria: -

Keywords: scd163 liver cirrhosis disease severity
effect of lactobacillus rhamnosus gg (lgg) on infant colic

Conditions: Colic; Inflammation

Summary: this study will compare 2 currently marketed formulas in healthy full term babies: nutramigen a+ (a hypoallergenic formula) and nutramigen-enflora (hypoallergenic formula with lactobacillus gg (lgg)) during 3 months of formula feeding. the investigators' aims are to compare 3 outcomes in these babies: (1) normal baby crying time; (2) the composition of intestinal microbiota (bacteria in the stool); and (3) a lab test which measures the number of white blood cells in the large intestine (fecal calprotectin). the investigators predict that lgg supplementation (nutramigen-enflora) will facilitate its establishment as an important component of the neonatal intestinal microbial community and reduce fecal calprotectin.


Eligibility criteria:
inclusion criteria: * sixty healthy full-term colicky infants (gestational age 32 wks to 41 wks) exclusion criteria: * chronic lung disease, * diarrhea (stools that take the shape of a container \> 5x daily) * fever

Keywords: lactobacillus probiotic crying time fecal microbiota calprotectin colic infant crying barr diary breath hydrogen clinical design
the prevalence of white spot lesions during orthodontic treatment with fixed appliances

Conditions: Dental Caries

Summary: this study investigates how often cavities develop on the permanent teeth of patients with braces (orthodontic treatment). the hypothesis is that there is no difference in the number of cavities on the permanent teeth of patients with braces compared to similar patients without braces.

the purpose of this cross-sectional study is to determine the prevalence of early carious lesions (white spot lesions, or wsls) for patients who are receiving orthodontic treatment compared to patients who are not receiving orthodontic treatment. subjects will be recruited from the university of kentucky orthodontic clinic patient pool. orthodontic care at the university of kentucky college of dentistry (ukcod) is provided by orthodontic faculty, as well as students enrolled in the graduate orthodontic program at the ukcod. subjects will be invited to participate in this study after receiving an initial treatment plan with fixed appliances for at least one arch.

Eligibility criteria:
inclusion criteria: * patients who agreed to participate in this study * patients who receive orthodontic treatment with fixed appliances at university of kentucky college of dentistry * patients who have either metal or ceramic brackets for the treatment exclusion criteria: * patients on a daily supplemental fluoride regimen * patients who has difficulty in their daily toothbrushing due to their physical disability * patients with lingual fixed appliances * patients who are pregnant * patients with restorations placed on the facial/buccal surface of the tooth from premolar to premolar for both arches.

Keywords: white spot lesions tooth